Evidence types
Basic science articles covering early-stage IBD research, disease mechanisms, lab findings, microbiome work, genetics, and experimental models.
Page 3 of 15 · 708 articles
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease, Microbiome, and Research and clinical trials. The original article is from Journal of genetics and...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Disinformation Security...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of Food Science...
The study helps explain how granulomas—linked to more severe Crohn’s disease—might form by repurposing lymphoid follicle macrophages, pointing to cellular programs and signals that could be relevant for future biomarkers...
This study helps pinpoint which gut cell types and regulatory DNA regions are most likely to mediate genetic risk for Crohn’s disease, which can guide future research toward relevant cells and pathways.
Researchers exploring new anti-inflammatory or metabolism-targeting approaches for UC might view KA as a candidate molecule that modulates arginine–polyamine metabolism, which could point to new drug-discovery...
STAT3 is a central immune signaling molecule implicated in ulcerative colitis; understanding its dual roles could influence future biomarker research and therapies for UC. The review highlights why STAT3’s...
This work organizes preclinical evidence connecting Atractylodes macrocephala constituents to intestinal barrier protection, immune modulation, and microbiota changes relevant to ulcerative colitis—useful for researchers...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of inflammation...
A new chemiluminescent probe could help researchers see and measure MPO-driven HOCl inflammation deeper in tissues, which may speed preclinical testing of IBD therapies and biomarker development.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Microbiome. The original article is from Folia Microbiologica.
If findings translate beyond mice, exposure to titanium dioxide during pregnancy could influence offspring gut barrier, microbiota, and susceptibility to inflammatory colitis — a potential public-health concern for...
The work suggests MSC-derived exosomes may reduce colitis and alter the gut microbiome and metabolites (notably SCFAs) in ways linked to lower inflammation, which could inspire future therapeutic research for IBD.
The paper points to S100A8 as a potential link between immune-cell-driven inflammation and mitochondrial stress in Crohn’s disease, which could help researchers explore new biomarkers or targets for study.
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Nature Communications.
This study proposes three autophagy-related genes (APOL1, CCL2, IL24) as potential biomarkers that may help classify ulcerative colitis patients into subtypes with different immune environments, which could eventually...
This preclinical study suggests raising mesaconate in the gut can reduce inflammation in mouse models of Crohn’s disease, using either an engineered probiotic or a zinc–mesaconate formulation—approaches that could...
This study links a neutrophil protein (ANXA3) to both ulcerative colitis and ischaemic stroke and suggests a compound (ginsenoside Rb1) can bind ANXA3 and reduce neutrophil hyperactivation in lab tests — a potential...
The work highlights molecular differences between PSC-UC and typical UC that could help explain higher colorectal cancer risk in PSC-UC and suggests candidate miRNA biomarkers (eg, miR-155) for further study.
Engineered extracellular vesicles are an emerging, targeted therapy approach that could someday improve immune control, mucosal healing, and drug delivery in IBD and reduce colitis-associated cancer risk. The review...
The paper suggests that changes in how microbes interact (community plasticity and network structure) may underlie microbiome differences seen in ulcerative colitis and could point toward ecology-informed biomarkers or...
This study identifies a new molecular pathway (JAK2–STAT4–AK4–mtDNA) linked to inflammatory macrophage activity in experimental colitis and presents a plant-derived alkaloid mixture (TAMR) that modulates that pathway....
The paper suggests a molecular link (RHBDF2–ADAM17–TNFα) between ulcerative colitis and blood–brain barrier disruption, which could explain some neurological comorbidities of UC and identify targets for future therapies.
Oral delivery of protective proteins or biologic therapies could make future IBD treatments easier to take and better at reaching the gut lining.
Researchers are exploring ways to deliver steroids to the inflamed gut while lowering systemic side effects; a nanoparticle carrier that protects the epithelium and concentrates drug in the colon could, if translated,...
The study suggests a noninvasive spleen-targeted ultrasound approach can reduce gut and brain inflammation and improve behavior in a mouse colitis model, mediated by vagal signaling—pointing to a possible new avenue for...
The study links T cell metabolism and epigenetics to inflammation in IBD, highlighting GSK3β as a possible drug target. That could guide future therapies aimed at dampening pathogenic T cells in Crohn’s disease.
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Genome Medicine.
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Research in pharmaceutical sciences.
The molecular interaction between acetylation and ubiquitination on NLRP3 and GSDMD could help explain mechanisms of inflammatory cell death relevant to UC and point to new biomarker or therapeutic targets, but direct...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from Journal of Translational Medicine.
Preclinical work identifies a natural-product mixture that reduced inflammation, improved gut barrier markers, and changed the microbiome in a mouse model of ulcerative colitis. This could be an early step toward new...
The study identifies a molecular epithelial program (GART-associated) linked to proliferation and purine metabolism in ulcerative colitis, which could inform future mechanistic research and biomarker development relevant...
The study suggests a new microbiota–metabolite–immune pathway (palmitic acid → PI3K/AKT → NETs) that may drive colitis and that Forsythia polysaccharides can modify, which could point to future microbiota-targeted...
The paper describes a novel colon-targeted delivery system that improved local drug retention, reduced dosing frequency, and changed microbiota and metabolic markers in a mouse model of UC — developments that could...
This project explores how CD74 in intestinal stem cells and Paneth cells helps control mucosal immune responses and epithelial repair — processes directly relevant to IBD pathogenesis and recovery.
The study explores a novel, non-invasive way to deliver an IL-23–blocking protein to the gut using engineered Lactococcus lactis, which could eventually offer an alternative to systemic biologics for controlling...
The study describes a new nanozyme-based oral formulation that reduced NET formation and improved mucosal healing in a mouse model of ulcerative colitis, suggesting a novel preclinical approach to long‑term...
This study explores a novel, non-invasive way to block IL-23 — an important inflammatory driver in IBD — by orally delivering small IL-23 inhibitors using engineered Lactococcus lactis in mouse colitis models.
Links between GWAS risk loci and the specific cell types where those loci may act can focus laboratory experiments and eventually help identify causal genes or pathways relevant to Crohn’s disease.
The review identifies a novel molecular mechanism (S-palmitoylation) that may drive barrier dysfunction and intestinal inflammation in IBD, suggesting new non-immunosuppressive therapeutic targets that could eventually...
The study presents a preclinical strategy to concentrate an existing antihistamine drug in the colon and reduce systemic exposure, which could improve local efficacy and safety for IBD treatment if later validated in...
Researchers report that a polysaccharide from Radix Hedysari reduced inflammation, improved barrier proteins, and shifted gut bacteria in a mouse model of ulcerative colitis — suggesting a potential preventive candidate...
Researchers are developing oral delivery methods to make promising anti‑inflammatory compounds more effective. If such platforms translate to humans, they could expand treatment options for UC by improving absorption of...
Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Enzyme and Microbial...
The paper identifies a specific probiotic strain that reduced colitis signs and improved intestinal barrier function in a mouse model, supporting further preclinical and translational work toward microbiome-based...
The study proposes a machine learning approach to identify SNPs linked to Crohn’s disease risk, which could help researchers prioritize genetic variants for further study and, eventually, contribute to risk prediction or...
New biomarkers and cell-type insights could help future diagnostic tools or targeted therapies in UC by pointing to TRP channel–related genes and B/plasma cell involvement.
